Literature DB >> 10562307

Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.

M Peakman1, E J Stevens, T Lohmann, P Narendran, J Dromey, A Alexander, A J Tomlinson, M Trucco, J C Gorga, R M Chicz.   

Abstract

During immune responses, antigen-presenting cells (APCs) process antigens and present peptide epitopes complexed with human leukocyte antigen (HLA) molecules. CD4 cells recognize these naturally processed and presented epitopes (NPPEs) bound to HLA class II molecules. Epitope identification is important for developing diagnostic and therapeutic tools for immune-mediated diseases and providing insight into their etiology, but current approaches overlook effects of natural processing on epitope selection. We have developed a technique to identify NPPEs using mass spectrometry (MS) after antigen is targeted onto APCs using a lectin-based antigen delivery system (ADS). We applied the technique to identify NPPEs of the intracellular domain of the type 1 diabetes mellitus-associated (type 1 DM-associated) autoantigen insulinoma-associated-2 (IA-2ic), presented by HLA-DR4 (0401). IA-2ic-derived NPPEs eluted from HLA-DR4 constitute 6 sets of peptides nested around distinct core regions. Synthetic peptides based on these regions bind HLA-DR4 and elicit primary T-cell proliferation frequently in HLA-DR4-positive type 1 DM patients, but rarely in non-HLA-DR4 patients, and in none of the HLA-DR4 nondiabetic controls we tested. This flexible, direct approach identifies an HLA allele-specific map of NPPEs for any antigen, presented by any HLA class II molecule. This method should enable a greater understanding of epitope selection and lead to the generation of sensitive and specific reagents for detecting autoreactive T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10562307      PMCID: PMC409844          DOI: 10.1172/JCI7936

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.

Authors:  R M Chicz; R G Urban; W S Lane; J C Gorga; L J Stern; D A Vignali; J L Strominger
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

2.  Minute quantities of a single immunodominant foreign epitope are presented as large nested sets by major histocompatibility complex class II molecules.

Authors:  D A Vignali; R G Urban; R M Chicz; J L Strominger
Journal:  Eur J Immunol       Date:  1993-07       Impact factor: 5.532

Review 3.  Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat.

Authors:  L Castaño; G S Eisenbarth
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

4.  HLA class II region sequences, 1998.

Authors:  S G Marsh
Journal:  Tissue Antigens       Date:  1998-04

5.  T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents.

Authors:  M C Honeyman; N L Stone; L C Harrison
Journal:  Mol Med       Date:  1998-04       Impact factor: 6.354

6.  Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase.

Authors:  W Richter; Y Shi; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

7.  HLA DR4 is associated with the development of multiple basal cell carcinomas and malignant melanoma.

Authors:  D Czarnecki; I Nicholson; B Tait; C Nash
Journal:  Dermatology       Date:  1993       Impact factor: 5.366

8.  Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes.

Authors:  L C Harrison; M C Honeyman; H J DeAizpurua; R S Schmidli; P G Colman; B D Tait; D S Cram
Journal:  Lancet       Date:  1993-05-29       Impact factor: 79.321

9.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.

Authors:  R M Chicz; R G Urban; J C Gorga; D A Vignali; W S Lane; J L Strominger
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

10.  Comparison of peptides bound to spleen and thymus class II.

Authors:  P Marrack; L Ignatowicz; J W Kappler; J Boymel; J H Freed
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  51 in total

1.  Selecting culprits in type 1 diabetes beta-cell killing.

Authors:  A Lernmark
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

3.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health.

Authors:  Sefina Arif; Timothy I Tree; Thomas P Astill; Jennifer M Tremble; Amanda J Bishop; Colin M Dayan; Bart O Roep; Mark Peakman
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 4.  T cell epitopes and post-translationally modified epitopes in type 1 diabetes.

Authors:  John W McGinty; Meghan L Marré; Veronique Bajzik; Jon D Piganelli; Eddie A James
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

5.  Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.

Authors:  Zemin Zhou; Eduardo Reyes-Vargas; Hernando Escobar; Brant Rudd; Alan L Rockwood; Julio C Delgado; Xiao He; Peter E Jensen
Journal:  Eur J Immunol       Date:  2016-01-22       Impact factor: 5.532

6.  Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes.

Authors:  J M Lawson; J Tremble; C Dayan; H Beyan; R D G Leslie; M Peakman; T I M Tree
Journal:  Clin Exp Immunol       Date:  2008-12       Impact factor: 4.330

7.  CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.

Authors:  Ania Skowera; Richard J Ellis; Ruben Varela-Calviño; Sefina Arif; Guo Cai Huang; Cassie Van-Krinks; Anna Zaremba; Chloe Rackham; Jennifer S Allen; Timothy I M Tree; Min Zhao; Colin M Dayan; Andrew K Sewell; Wendy W Unger; Wendy Unger; Jan W Drijfhout; Ferry Ossendorp; Bart O Roep; Mark Peakman
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

8.  The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes.

Authors:  Stef J Bloem; Bart O Roep
Journal:  Diabetologia       Date:  2017-04-24       Impact factor: 10.122

Review 9.  Islet autoantigens: structure, function, localization, and regulation.

Authors:  Peter Arvan; Massimo Pietropaolo; David Ostrov; Christopher J Rhodes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  Cytokine-induced dicing and splicing in the beta-cell and the immune response in type 1 diabetes.

Authors:  John C Hutton; Howard W Davidson
Journal:  Diabetes       Date:  2010-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.